Rep. Barton asks FDA if internal probe of data release to Summit precludes criminal prosecution.
This article was originally published in The Gray Sheet
Executive Summary
REP. BARTON DETERMINING IF "POSSIBLE CRIMINAL PROSECUTION" FOR FDA DATA RELEASE to Summit Technology has been "jeopardized" by FDA's in-house investigation of the agency's late-November breach of confidentiality. In a May 22 letter to FDA Commissioner David Kessler, Rep. Joe Barton (R-Tex.), chairman of the House Commerce/Oversight Subcommittee, states that "the subcommittee needs to be assured that the conduct of FDA's internal investigation has not jeopardized a possible referral or possible criminal prosecution."